Lung Therapeutics | LinkedIn (original) (raw)

``

Biotechnology Research

Austin, TX 1,910 followers

Lung Therapeutics is developing first-in-class medicines for unmet medical needs in fibrosis and lung disease.

About us

In October, 2023 Lung Therapeutics was acquired by Aileron Therapeutics. Aileron is now a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit https://aileronrx.com

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Austin, TX

Type

Public Company

Founded

2013

Locations

Employees at Lung Therapeutics

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding